Global Acamprosate Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Acamprosate Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Campral is a brand name of Acamprosate, and Acamprosate is sold under the brand name Campral, Acamprosate calcium is a synthetic compound with a chemical structure similar to that of the endogenous amino acid homotaurine, which is a structural analogue of the amino acid neurotransmitter γ-aminobutyric acid and the amino acid neuromodulator taurine. Its chemical name is calcium acetylaminopropane sulfonate. Each Campral® tablet contains acamprosate calcium 333 mg, equivalent to 300 mg of acamprosate. Inactive ingredients in Campral tablets includecrospovidone, microcrystalline cellulose, magnesium silicate, sodium starch glycolate, colloidal anhydrous silica, magnesium stearate, talc, propylene glycol and Eudragit L 30 D or equivalent. Sulfites were used in the synthesis of the drug substance and traces of residual sulfites may be present in the drug product.
Acamprosate report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Acamprosate market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Hospital and Clinic are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Acamprosate industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Acamprosate key manufacturers include Merck Group, Zydus Pharmaceuticals, Mylan, Teva and Glenmark Pharmaceuticals, etc. Merck Group, Zydus Pharmaceuticals, Mylan are top 3 players and held % sales share in total in 2022.
Acamprosate can be divided into 333 mg Delayed Release Tablet and Others, etc. 333 mg Delayed Release Tablet is the mainstream product in the market, accounting for % sales share globally in 2022.
Acamprosate is widely used in various fields, such as Hospital, Clinic and Others,, etc. Hospital provides greatest supports to the Acamprosate industry development. In 2022, global % sales of Acamprosate went into Hospital filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Acamprosate market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Merck Group
Zydus Pharmaceuticals
Mylan
Teva
Glenmark Pharmaceuticals
Segment by Type
333 mg Delayed Release Tablet
Others
Hospital
Clinic
Others
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Acamprosate market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Acamprosate, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Acamprosate industry.
Chapter 3Historical (2024-2022) and forecast (2024-2034) volume and revenue analysis of Acamprosate in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Acamprosate introduction, etc. Acamprosate Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Acamprosate market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Acamprosate report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Acamprosate market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Hospital and Clinic are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Acamprosate industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Acamprosate key manufacturers include Merck Group, Zydus Pharmaceuticals, Mylan, Teva and Glenmark Pharmaceuticals, etc. Merck Group, Zydus Pharmaceuticals, Mylan are top 3 players and held % sales share in total in 2022.
Acamprosate can be divided into 333 mg Delayed Release Tablet and Others, etc. 333 mg Delayed Release Tablet is the mainstream product in the market, accounting for % sales share globally in 2022.
Acamprosate is widely used in various fields, such as Hospital, Clinic and Others,, etc. Hospital provides greatest supports to the Acamprosate industry development. In 2022, global % sales of Acamprosate went into Hospital filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Acamprosate market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Merck Group
Zydus Pharmaceuticals
Mylan
Teva
Glenmark Pharmaceuticals
Segment by Type
333 mg Delayed Release Tablet
Others
Segment by Application
Hospital
Clinic
Others
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Acamprosate market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Acamprosate, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Acamprosate industry.
Chapter 3Historical (2024-2022) and forecast (2024-2034) volume and revenue analysis of Acamprosate in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Acamprosate introduction, etc. Acamprosate Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Acamprosate market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices